Home Immunology & Inflammation NOS chemical L-Arginine HCl (L-Arg)

research use only

L-Arginine HCl (L-Arg) NOS chemical

Cat.No.S3174

L-Arginine HCl (L-Arg, (S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. This compound can be used to induce animal models of Acute Pancreatitis.
L-Arginine HCl (L-Arg) NOS chemical Chemical Structure

Chemical Structure

Molecular Weight: 210.66

Jump to

Quality Control

Batch: Purity: 99.33%
99.33

Solubility

In vitro
Batch:

Water : 42 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 210.66 Formula

C6H14N4O2.HCl

 Storage (From the date of receipt)
CAS No. 1119-34-2 Download SDF Storage of Stock Solutions

Synonyms (S)-(+)-Arginine hydrochloride SMILES C(CC(C(=O)O)N)CN=C(N)N.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

L-Arginine HCl (L-Arg) supplementation (0.3 mM, 30 minutes) does not induce any significant increases in the peak NO concentration at low level of native LDL. However, at native LDL concentrations from 60-130 mg cholesterol/dL, NO concentration is 2 times higher than before treatment in bovine aortic endothelial cells. This compound results in a significant increase of NO production in n-LDL–treated cells as well as in oxidized -LDL–treated cells in the same cell type. It does not increase O2- concentration at low nativeLDL concentrations but reduces O2- production by 50% when incubated with n-LDL at concentrations >40 mg cholesterol/dL. Furthermore, it completely abolishes O2- production at every oxidized LDL dosage in bovine aortic endothelial cells.

In vivo

L-Arginine HCl (L-Arg) (4 mg/kg/min for 1 hour) treatment decreases superoxide generation by cNOS while increasing NO accumulation in rabbit limb during ischemia/reperfusion. This compound prevents microvessel constriction in the reperfused muscle despite reduced but still apparent interstitial edema in rabbit limb, and results in a significant reduction of muscular reperfusion edema in rabbit limb. Its supplementation (0.1 g/kg, oral) significantly reduces pulmonary artery systolic pressure by a mean of 15.2% after 5 days of therapy in patients with sickle cell disease. Both L-Arginine and ornithine concentrations increased significantly after 5 days of oral supplementation in patients with sickle cell disease. It is associated with a decrease in cardiac index while stroke index is maintained in patients with severe sepsis. Resolution of shock at 72 hours is achieved by 40% and 24% of the patients in the L-Arginine and placebo cohorts, respectively. This compound (450 mg/kg during a 15-minute period) amplifies and sustains the hyperemia (38%) and increases absolute brain blood flow after eNOS upregulation by chronic simvastatin treatment (2 mg/kg subcutaneously, daily for 14 days) in SV-129 mice.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/14707554/
  • [5] https://pubmed.ncbi.nlm.nih.gov/10779015/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-09-17)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06860724 RECRUITING
Major Depressive Disorder
University of Delaware
 2025-01-06
NCT07772882 NOT_YET_RECRUITING
Platinum Resistant Ovarian Cancer; Fallopian Tube Cancers; Peritoneal Carcinoma
Rebecca Arend
 2026-09 PHASE1
NCT04800692 ACTIVE_NOT_RECRUITING
Claudication, Intermittent; Peripheral Artery Disease; Peripheral Vascular Diseases
Louis Messina
 2021-06-15 PHASE1
NCT07394270 NOT_YET_RECRUITING
Heart Failure
German University in Cairo
 2026-02 PHASE2
NCT03982160 ACTIVE_NOT_RECRUITING
Chronic Kidney Disease
The University of Texas at Arlington
 2018-02-01 PHASE4
NCT07150806 RECRUITING
Recurrent Meningioma
Joshua Palmer
 2025-11-12 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.